DiscernDx Acquires Luminist Labs
April 29, 2020
DiscernDx, a Palo Alto precision medicine company, has acquired Luminist Labs, a privately-held diagnostic platform developer focused on early detection and diagnosis of liver disease. The acquisition will integrate Luminist's data and platform into DiscernDx's multi-omics system to accelerate development of non-invasive diagnostic and prognostic solutions for NASH and other chronic metabolic liver diseases. Terms were not disclosed.
- Buyers
- DiscernDx
- Targets
- Luminist Labs
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.